Open AccessA systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors
Author(s) -
Eduardo Rodriguez Almaraz,
Susan M. Chang,
Jennifer Clarke,
Nancy Ann Oberheim-Bush,
Jennie Taylor,
Robin Buerki,
Mitchell S. Berger,
Lydia B. Zablotska,
Iryna Lobach,
Nicholas Butowski
Publication year - 2020
Publication title -
neuro-oncology practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 14
eISSN - 2054-2585
pISSN - 2054-2577
DOI - 10.1093/nop/npaa013
Subject(s) - medicine , cannabis , publication bias , meta analysis , brain tumor , oligodendroglioma , oncology , systematic review , medline , relative risk , effects of cannabis , clinical trial , glioma , cannabidiol , confidence interval , pathology , psychiatry , astrocytoma , cancer research , political science , law
Primary CNS tumors constitute a heterogeneous group of neoplasms that share a considerable morbidity and mortality rate. To help control tumor growth and clinical outcomes (overall survival, progression-free survival, quality of life) symptoms, patients often resort to alternative therapies, including the use of cannabis. Despite rapidly growing popularity, cannabis and its impact on patients with primary malignant CNS tumors is understudied.